Cholinesterase Inhibitors in Parkinson's Disease

D. Aarsland; C. Ballard

doi:10.1016/B978-0-12-374105-9.00147-7

Cholinesterase Inhibitors in Parkinson's Disease

D. Aarsland^*, C. Ballard

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Cholinergic deficits are marked in Parkinson's disease (PD), and are associated with cognitive impairment and hallucinations. There is emerging evidence suggesting that cholinesterase inhibitors improve cognition, attention, and functioning in PD, although the improvement is modest. Mild and transient worsening of tremor occurs, in addition to nausea and other peripheral cholinergic side effect.

Original language	English
Title of host publication	Encyclopedia of Movement Disorders
Publisher	Elsevier Inc.
Pages	208-211
Number of pages	4
ISBN (Electronic)	9780123741059
ISBN (Print)	9780123741011
DOIs	https://doi.org/10.1016/B978-0-12-374105-9.00147-7
Publication status	Published - 2010

Keywords

Cholinesterase inhibitors
Cognitive impairment
Dementia
Donepezil
Galantamine
Hallucinations
Parkinson's disease
Rivastigmine

Access to Document

10.1016/B978-0-12-374105-9.00147-7

Cite this

@inbook{6a0931c4335d4f88b6432d229a6a1685,

title = "Cholinesterase Inhibitors in Parkinson's Disease",

abstract = "Cholinergic deficits are marked in Parkinson's disease (PD), and are associated with cognitive impairment and hallucinations. There is emerging evidence suggesting that cholinesterase inhibitors improve cognition, attention, and functioning in PD, although the improvement is modest. Mild and transient worsening of tremor occurs, in addition to nausea and other peripheral cholinergic side effect.",

keywords = "Cholinesterase inhibitors, Cognitive impairment, Dementia, Donepezil, Galantamine, Hallucinations, Parkinson's disease, Rivastigmine",

author = "D. Aarsland and C. Ballard",

year = "2010",

doi = "10.1016/B978-0-12-374105-9.00147-7",

language = "English",

isbn = "9780123741011",

pages = "208--211",

booktitle = "Encyclopedia of Movement Disorders",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Cholinesterase Inhibitors in Parkinson's Disease

AU - Aarsland, D.

AU - Ballard, C.

PY - 2010

Y1 - 2010

N2 - Cholinergic deficits are marked in Parkinson's disease (PD), and are associated with cognitive impairment and hallucinations. There is emerging evidence suggesting that cholinesterase inhibitors improve cognition, attention, and functioning in PD, although the improvement is modest. Mild and transient worsening of tremor occurs, in addition to nausea and other peripheral cholinergic side effect.

AB - Cholinergic deficits are marked in Parkinson's disease (PD), and are associated with cognitive impairment and hallucinations. There is emerging evidence suggesting that cholinesterase inhibitors improve cognition, attention, and functioning in PD, although the improvement is modest. Mild and transient worsening of tremor occurs, in addition to nausea and other peripheral cholinergic side effect.

KW - Cholinesterase inhibitors

KW - Cognitive impairment

KW - Dementia

KW - Donepezil

KW - Galantamine

KW - Hallucinations

KW - Parkinson's disease

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=85069832201&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374105-9.00147-7

DO - 10.1016/B978-0-12-374105-9.00147-7

M3 - Chapter

AN - SCOPUS:85069832201

SN - 9780123741011

SP - 208

EP - 211

BT - Encyclopedia of Movement Disorders

PB - Elsevier Inc.

ER -

Cholinesterase Inhibitors in Parkinson's Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this